Watch TXMD. Know when insiders buy.
One email the day a filing lands. Free.
TXMD
TherapeuticsMD, Inc.
2.03
+0.00 +0.00%
USD · close Oct 1
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
62
WATCH · shorts 62
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $23.5MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$217KNET DEBT $87.9M52W 1.04 – 2.77SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$816K | $155K | −71.9% | 0.01 | $779K | — | — | Aug 11 |
| Q1 2026 · Mar 31 | $724K | +84.2% | — | −$723K | $95K | — | 0.01 | $944K | — | — | Aug 11 |
| Q4 2025 · Dec 31derived | — | — | — | −$1.6M | −$619K | −345.6% | -0.05 | $375K | — | — | Apr 1 |
| Q3 2025 · Sep 30 | — | — | — | −$862K | $152K | — | 0.01 | $999K | — | — | Nov 12 |
| Q2 2025 · Jun 30 | — | — | — | −$695K | $551K | — | 0.05 | $381K | — | — | Aug 11 |
| Q1 2025 · Mar 31 | $393K | — | — | −$1.3M | −$653K | — | -0.06 | $699K | — | — | Aug 11 |
| Q4 2024 · Dec 31derived | — | — | — | −$652K | $252K | — | 0.02 | $17K | — | — | Apr 1 |
| Q3 2024 · Sep 30 | — | — | — | −$1.1M | −$609K | — | -0.05 | −$71K | — | — | Nov 12 |
| Q2 2024 · Jun 30 | — | — | — | −$2.8M | −$1.1M | — | -0.09 | $1.5M | — | — | Nov 12 |
| Q1 2024 · Mar 31 | — | — | — | −$1.1M | −$734K | — | -0.06 | −$229K | — | — | Nov 12 |
| Q4 2023 · Dec 31derived | $502K | — | 100.0% | −$1.6M | −$883K | — | -0.07 | −$5M | — | — | Mar 27 |
| Q3 2023 · Sep 30 | −$53K | — | 100.0% | −$1.8M | −$3.4M | — | -0.32 | −$6M | — | — | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$4.4M | −$569K | — | -0.05 | $2.5M | — | — | — | — |
| FY2024 · to Dec 31 | $1.8M | — | −$6.1M | −$2.2M | -123.9% | -0.19 | $1.2M | — | — | — | — |
| FY2023 · to Dec 31 | $1.3M | 100.0% | −$8.5M | −$10.3M | -789.4% | -0.99 | −$23.1M | — | — | — | — |
| FY2022 · to Dec 31 | $70M | 98.0% | $1.2M | $112M | 160.1% | 11.96 | $9.4M | — | — | — | — |
| FY2021 · to Dec 31 | $2.6M | 45.5% | −$79.6M | −$172.4M | -6700.9% | -21.66 | −$142.7M | $34K | −$142.7M | — | — |
| FY2020 · to Dec 31 | $64.9M | 75.4% | −$155.5M | −$183.5M | -282.9% | -0.67 | −$159.5M | $207K | −$159.7M | — | — |
Every number comes from TherapeuticsMD, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.